News

The healthcare costs of myasthenia gravis (MG) are high, according to a study from Denmark, Finland, and Sweden, and even higher for women and patients with very severe symptoms or coexisting conditions such as mental health problems or severe infections. A large portion of direct costs in all three…

Among people with myasthenia gravis (MG), the degree of daily activity impairment is greater for those with more severe and more widespread muscle weakness, according to real-world data from a survey of physicians in the U.S. and Europe. However, the study — which involved clinicians treating more than…

A bacterial enzyme called CU43 potently mitigates the impact of the self-reactive antibodies that drive myasthenia gravis (MG) and other autoimmune diseases, according to data from a preclinical study. The research team, led by scientists at Emory University in Georgia, in collaboration with researchers at Rockefeller University in New…

The new UCB Myasthenia Gravis Scholarship, launched by the Belgium-based biopharmaceutical company, is aiming to help myasthenia gravis (MG) patients and their family members in the U.S. to continue their education or learn new skills by covering educational expenses — with program awards totaling up to $150,000. “We…

Johnson & Johnson’s nipocalimab appears to be safe and to ease symptoms of generalized myasthenia gravis (gMG) in adolescents with antibodies against the acetylcholine receptor, the most common type of MG-causing antibody, according to six-month data from an open-label clinical trial. The Phase 2/3 Vibrance-MG study…

Two doses of inebilizumab, Amgen’s antibody-based therapy, led to sustained reductions in the severity of generalized myasthenia gravis (gMG) among patients for up to six months, meeting the primary goal of an ongoing Phase 3 clinical trial. The trial, called MINT (NCT04524273), demonstrated that inebilizumab’s benefits extend…

Descartes-08, an investigational CAR T-cell therapy for generalized myasthenia gravis (gMG), markedly reduced disease activity among patients who completed the entire protocol of a three-month Phase 2b clinical trial. The treatment was also associated with reduced levels of MG-driving self-reactive antibodies, but not in the broader antibody…

More than half of adults with generalized myasthenia gravis (gMG) show a clinically meaningful response to Ultomiris (ravulizumab-cwvz) within about two weeks of a first dose, according to a post-hoc analysis of clinical trial data. In contrast, more than 80% of these 139 trial patients experienced a meaningful…

Myasthenia gravis (MG) cases increased gradually from 2000 to 2020 in Denmark, Finland, and Sweden, with the total number of cases and the number of newly diagnosed cases both rising, according to a population-based study. The number of newly diagnosed cases was higher among men older than 50 and…

An artificial intelligence (AI)-powered analysis of more than 11,000 posts on social media or in online community groups found that myasthenia gravis (MG) patients use these platforms primarily to discuss the negative impact of their disease symptoms and their feelings about MG treatments. Most of the posts…